anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: We assessed the quality of life, sleep, depression, anxiety, and stress in people with pharmacoresistant epilepsy (PRE) and newly diagnosed epilepsy (NDE). We also assessed the influence of sleep, depression, anxiety, and stress on the quality of life (QOL) and the complex association between these factors.
METHODS: We recruited 80 PRE and 70 NDE people attending the epilepsy clinic. We assessed QOL, sleep quality, daytime sleepiness, and mood using the quality of life in epilepsy-31 inventory (QOLIE-31), Pittsburgh sleep quality index (PSQI), Epworth sleepiness scale (ESS), and depression anxiety stress scale (DASS-21). We compared the results between the two groups of epilepsy populations. We performed univariate and multivariate linear regression to determine the factors affecting the QOLIE-31 total score. We applied Spearman's rank correlation to find the interrelationship between variables influencing QOL.
RESULTS: We found significantly lower QOLIE-31 total scores (p = .001) in PRE compared to NDE. The PSQI and ESS did not differ significantly between the PRE and NDE groups. Anxiety (p = .002) and stress (p = .003) scores were significantly higher in PRE than in NDE. QOLIE-31 total scores showed a negative correlation with PSQI as well as symptoms of depression, anxiety, and stress scores in both groups. Multiple linear regression analysis revealed depression as a major factor influencing the QOLIE-31 total score in PRE (p = .001) and NDE (p = .003). We found significant complex associations between PSQI, depression, anxiety, stress, and QOLIE total scores in both groups.
SIGNIFICANCE: The QOL is poorer for people with PRE than for those with NDE. Depression is a major determinant of QOL in PWE. These factors need to be considered to improve the QOL in epilepsy.
Both groups of patients were provided with routine treatments, including pharmacological treatment, rehabilitation therapy.Based on this, the patients in the observation group were given enteral nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University).
Patients in the durvalumab (MEDI4736) + tremelimumab combination therapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months until confirmed disease progression unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. The first durvalumab (MEDI4736) monotherapy dose at 1500mg Q4W will be within 8 weeks after the completion of adjuvant therapy.
BACKGROUND: The Rey's 15 words test is currently the most frequently used task in Italy to detect memory deficits in AD. The current standardised version is however quite outdated and lacks some cognitive indexes which may highlight problems in recall or encoding processes. The aim of the study was to update the normative data of the test and to consider some variables which were not accounted for in the original study, that is, recognition, learning rate and forgetfulness. We also adopted the process scores approach to ascertain the effects of serial position (primacy and recency).
METHODS: Three hundred ninety-six healthy participants were recruited. To detect any variables useful for intercepting the early stages of dementia, a group of 208 patients in the very early stage of AD was also recruited. Linear models were used to calculate the corrections scores for age, education, and gender, and ROCs were used to calculate cut-offs based on the maximum sum of sensitivity and specificity and the positive and negative predictive values.
RESULTS: All main indexes showed excellent Area Under the Curve (0.90-1), strong sensitivity and PPVs for distinguishing between the HCs and AD participants. However, the Intrusions index performed poorly in all parameters.
CONCLUSION: The study provides updated, normative data which may be reliably used as a cognitive marker to detect early AD. The strength of the study is the large sample size and the number of indexes which make it possible to explore the utility of memory test process scores.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to neurooncology, and may be used for the intraoperative diagnosis of cerebral and spinal tumour borders and determination of the tumour resection quality. What is presented is an intraoperative combined spectroscopic diagnostic technique for cerebral and spinal tumours which involve the preoperative preparation including the oral administration of hydrochloride-5-aminolevulinic acid (several hours before the tumour resection). Actually the intraoperative spectroscopic analysis of the tumour marker content in the analysed tissues (5-aminolevelinic acid-induced protoporphyrin IX), as well as its desintegration products, oxygenated and reduced hemoglobin; the tissue scattering properties are varied using broadband and laser geode light source and a fibre-optic probe. The broadband light source is used within the range of 500÷600 nm, while the exiting fluorescent laser/diode light source - at wave length 620÷640 nm. The diffuse-reflectance spectra of the broadband and laser/diode light, as well as fluorescence are recorded at the same time. After the spectroscopic characteristics have been automatically classified, the operative radicality is assessed.EFFECT: presented method enables higher reliability of the intraoperative measurements in neuronavigation, reducing time needed for implementing them, providing deeper probing and simplifying the spectra recording in vivo.4 cl, 9 dwg, 3 ex
FIELD: medicine, pharmacology. SUBSTANCE: invention relates to the unknown complex of arginine and hyaluronic acid that shows capability to decrease blood cholesterol in warm-blooded animals. Method of preparing the indicated complex involves heating the suspension of 1 mas. p. arginine and 2-4 mas. p. hyaluronic acid in 40-50 mas. p. water at 80-90 C for 1-2 h. Solution is cooled to 4-6 C, ethanol (4-6 volumes) is added, precipitate is removed, washed many times with ethanol and dried in the air. After a single administration of this complex at low doses in blood stream of animals the content of blood cholesterol is decreased for a long time. EFFECT: enhanced effectiveness of agent. 2 cl, 2 tbl
<P>PROBLEM TO BE SOLVED: To provide information of an optimum treatment method to a user using medical products or the like held in a first aid box.  <P>SOLUTION: The user connects a portable terminal by a cable or the like to the first aid box mounted with an interrogator for RF-ID tags holding medical products or the like with RF-ID tags, and an RF-ID tag mounted user ID card recording user information. After the portable terminal automatically recognizes the medical products or the like with the RF-ID tags, and the RF-ID tag mounted user ID card held by the medical product box mounted with the interrogator for RF-ID tags, it sends an automatic recognition result to a server system via the Internet. The server system selects a treatment method ideal for the user by the automatic recognition result or the like, and it sends the optimum treatment method to the portable terminal via the Internet. The portable terminal displays the optimum treatment method sent from the server system in a display screen.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Participants in METWI2 undergo both a baseline (unrestricted) sleep and sleep restriction condition. On the morning following each condition, participants complete an oral glucose tolerance test to measure changes in glucose and insulin following ingestion of a glucose load.
After hemorrhage control, pulp chamber was cleansed with physiologic saline prior the CH pulpotomy.Then, canal orifices were sealed with CH (Kalsin, Aktu, Izmir, Turkey) paste (CH powder mixed with physiologic saline). After the canal orifice dressing, the chamber was based with reinforced ZOE (IRM; Dentsply Caulk, Milford, DE) and the tooth immediately restored with a stainless steel crown (SSC; 3M ESPE, Seefeld, Germany).
Inherited ichthyosis comprises a series of heterogeneous dermal conditions; it mainly manifests as widespread hyperkeratosis, xerosis and scaling of the skin. At times, overlapping symptoms require differential diagnosis between ichthyosis and several other similar disorders. The present study reports seven patients with confirmed or suspected to be associated with ichthyosis by conducting a thorough clinical and genetic investigation. Genetic testing was conducted using whole‑exome sequencing, with Sanger sequencing as the validation method. The MEGA7 program was used to analyze the conservation of amino acid residues affected by the detected missense variants. The enrolled patients exhibited ichthyosis‑like but distinct clinical manifestations. Genetic analysis identified diagnostic variations in the FLG, STS, KRT10 and SERPINB7 genes and clarified the carrying status of each variant in the respective family members. The two residues affected by the detected missense variants remained conserved across multiple species. Of note, the two variants, namely STS: c.452C>T(p.P151L) and c.647_650del(p.L216fs) are novel. In conclusion, a clear genetic differential diagnosis was made for the enrolled ichthyosis‑associated patients; the study findings also extended the mutation spectrum of ichthyosis and provided solid evidence for the counseling of the affected families.
Isolated chondrocytes are propagated in the presence of a biological gel such as a fibrin gel to generate a cartilage matrix that firmly bonds together two adjacent cartilage pieces. A bonding composition containing the isolated chondrocytes mixed with the biological gel is applied to a surface of one (or both) of the cartilage pieces, and the surface is contacted with the other cartilage piece. In a different order of steps, the two cartilage pieces are held in apposition, and gaps at the interface are filled with the bonding composition. In another method, either or both of the cartilage pieces are first incubated with the isolated chondrocytes, the biological gel is then applied, and the cartilage pieces are held together. Alternatively, after incubating with isolated chondrocytes, the biological gel can be applied to fill gaps at the interface between cartilage pieces held in apposition. One or both of the cartilage pieces can be depleted of endogenous chondrocytes before bonding, and the cartilage pieces can be articular cartilage, fibrocartilage or growth cartilage. A cartilage implant is formed by incubating isolated chondrocytes with a cartilage piece and applying the biological gel to the incubated cartilage piece. In repairing defective articular cartilage in a mammal, one of the pieces to be bonded is the defective cartilage and the other piece is the cartilage implant. A meniscal tear in fibrocartilage is another cartilage defect that can be repaired.
The goal of replacement therapy is to achieve and maintain a clinical and biochemical euthyroid state. The goal of suppressive therapy is to inhibit growth and/or function of abnormal thyroid tissue. The dose of SYNTHROID that is adequate to achieve these goals depends on a variety of factors including the patient's age, body weight, cardiovascular status, concomitant medical conditions, including pregnancy, concomitant medications, and the specific nature of the condition being treated (see WARNINGS and PRECAUTIONS). Hence, the following recommendations serve only as dosing guidelines. Dosing must be individualized and adjustments made based on periodic assessment of the patient's clinical response and laboratory parameters (see PRECAUTIONS - Laboratory Tests).

SYNTHROID is administered as a single daily dose, preferably one-half to one-hour before breakfast. SYNTHROID should be taken at least 4 hours apart from drugs that are known to interfere with its absorption (see PRECAUTIONS - Drug Interactions).

Due to the long half-life of levothyroxine, the peak therapeutic effect at a given dose of levothyroxine sodium may not be attained for 4-6 weeks.

Caution should be exercised when administering SYNTHROID to patients with underlying cardiovascular disease, to the elderly, and to those with concomitant adrenal insufficiency (see PRECAUTIONS).
The present invention relates to an apparatus for task determination during brain activity analysis. The apparatus comprises an input unit ( 20 ), a processing unit ( 30 ), and an output unit ( 40 ). The input unit is configured to provide the processing unit with measurement data of the brain of a patient performing a task during brain activity analysis. The processing unit is configured to determine a measure of brain activity based on the measurement data of the brain. The processing unit is configured to determine: that the patient should perform a different task to the task they are currently performing and select the different task; or that the patient should continue performing the task that they are currently performing; or that the patient should stop performing the task; The determination comprises utilization of information relating to the task and the determined measure of brain activity and information relating to a plurality of reference tasks and associated plurality of reference measures of brain activity. The output unit is configured to output an indication that the patient should perform the different task, that the patient should continue performing the task, or that the patient should stop performing the task.
PURPOSE:To carry out the test of the internal and external secretion function of the pancreas, easily and accurately, by administering an activator which converts an inactive plasminogen to an active plasmin to the human body in combination with a pancreas stimulating agent. CONSTITUTION:Blood is collected from human body in the hungry state. An activator which converts a plasminogen to an active plasmin (e.g. streptokinase) and a pancreas stimmulating agent (e.g. secretin) are dissolved in a physiological saline water, and administered to the man by intravenous injection or dripping. Blood serum specimens are collected from the body after the administration for 2hr at intervals of 30min, and the contents of amylase, glucagon, insulin, blood sugar, neutral fat, cholesterol, electrolytes, somastatin, etc. in each specimen are determined. The pancreatic diseases can be diagnosed from the state of the internal and external secretion function of the pancreas judged from the data obtained above. EFFECT:It is not necessary to insert a probe, etc. deep into the body, and the contents of the blood components can be determined accurately without the problems such as the stimulation of other organs.
The intimate relationship between the epithelium and immune system is crucial for maintaining tissue homeostasis, with perturbations therein linked to autoimmune disease and cancer1-3. Whereas stem cell-derived organoids are powerful models of epithelial function4, they lack tissue-resident immune cells that are essential for capturing organ-level processes. We describe human intestinal immuno-organoids (IIOs), formed through self-organization of epithelial organoids and autologous tissue-resident memory T (TRM) cells, a portion of which integrate within the epithelium and continuously survey the barrier. TRM cell migration and interaction with epithelial cells was orchestrated by TRM cell-enriched transcriptomic programs governing cell motility and adhesion. We combined IIOs and single-cell transcriptomics to investigate intestinal inflammation triggered by cancer-targeting biologics in patients. Inflammation was associated with the emergence of an activated population of CD8+ T cells that progressively acquired intraepithelial and cytotoxic features. The appearance of this effector population was preceded and potentiated by a T helper-1-like CD4+ population, which initially produced cytokines and subsequently became cytotoxic itself. As a system amenable to direct perturbation, IIOs allowed us to identify the Rho pathway as a new target for mitigation of immunotherapy-associated intestinal inflammation. Given that they recapitulate both the phenotypic outcomes and underlying interlineage immune interactions, IIOs can be used to study tissue-resident immune responses in the context of tumorigenesis and infectious and autoimmune diseases.
A method for evaluating positioning of an examination object on a patient-positioning apparatus in a magnetic resonance unit, a magnetic resonance unit, and a computer program product are provided. The method includes acquiring positioning data relating to the examination object using an acquisition unit. Using the acquired positioning data, positioning information relating to the examination object is determined using an analysis unit. Evaluation information is determined using the positioning information, using an evaluation unit. Using the evaluation information, an evaluation signal is transmitted using an output unit. Monitoring of a specific absorption rate may be adjusted using the evaluation signal.
The invention discloses application of Gastrodia Elata Bl. and an extract of Gastrodia Elata Bl. in preparation of medicine for treating and repairing peripheral nerve injury. Gastrodia Elata Bl. or extract of Gastrodia Elata Bl. is independently made into powder, capsule, tablet or injection; or made into compound preparation together with other medicinal materials. According to the invention, a kind of novel medicine which is used for treating and repairing peripheral nerve injury, is low in cost and has reliable effects is provided.
Systems and method for communication of information to one or more medical care providers. The systems and methods may utilize a client with which a user may interact. As such, the user may utilize the client to research, display, and/or select a medical care provider. The user may input information to the client which is transmitted to a selected medical care provider prior to the user arriving at the medical care provider's facility. This may include an indication of the user's intent to visit the medical care provider. As such, the medical care provider may utilize the data received to generate a chart and make preparations (e.g., reserve resources) in anticipation of the user's visit. The user may also use the client to access and/or share a personal health record.
BACKGROUND: Angiosarcoma of the adrenal gland is a very rare malignant vascular neoplasm. The clinical symptoms are atypical or completely absent. Angiosarcomas of the adrenal gland are therefore often discovered incidentally, and the diagnosis is made histologically after resection.
CASE PRESENTATION: A 46-year-old white Spanish male who was a previous smoker and nondrinker and was slightly overweight (92 kg, 176 cm, body mass index 29.7 kg/m2) with no relevant medical history presented to the internal medicine emergency department of our hospital with an unclear 12 cm tumor of the right adrenal gland. Prior to the computed tomography scan, he had had persistent evening fevers for 4 months and unintentional weight loss of 5 kg. The laboratory results showed anemia and an elevated C-reactive protein, but no hormone production. We performed an open adrenalectomy of the right adrenal gland. Finally, the histologic findings revealed an angiosarcoma of the adrenal gland.
CONCLUSION: Even though angiosarcomas of the adrenal gland are rare, the differential diagnosis of an angiosarcoma should be considered if a malignant tumor of the adrenal gland is suspected. Treatment decisions should be made on an interdisciplinary basis and preferably in a specialized center. Owing to the rarity of angiosarcomas of the adrenal gland, it is necessary to continue to share clinical experience to gain a better understanding of this particular tumor entity.
The utility model provides a calcium carbonate tablet with a through hole or an opening. The surface of the through hole or the opening has no coatings. After the calcium carbonate tablet reaches the stomach, the calcium carbonate can generate the calcium chloride which is easy to be absorbed and can generate the carbon dioxide which helps to collapse of soaks through direct reaction of the calcium carbonate with the gastric hydrochloric acid. The tablet for protecting the bone density provided by the utility model is preferably composed of the 300-600 mg. Calcium carbonate and the 50-200 mg. Bitter salt. The tablet which has cheap manufacturing cost and simple process is favorable to be widely used and manufactured.
Patients receive floxuridine and dexamethasone intra-arterially continuously on days 1-14, oxaliplatin IV over 2 hours on day 22, and oral capecitabine twice daily on days 22-35. Treatment repeats every 6 weeks for 4 courses in the absence of disease recurrence or unacceptable toxicity. After completion of the fourth course, patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 3 weeks for 2 courses in the absence of disease recurrence or unacceptable toxicity.
After extraction intervention will include the placement of CoreBone500 device derived from coral that is particulate. 0.3-0.5cc for each extraction socket.Its advantage is that it fills well the socket site.Measurements from models taken at different times will be analysed for bone loss. Changes in width and height of alveolar bone will be studied at 3 and 6 month.
Twelve healthy, normal weight subjects (male: 6, female: 6) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from white bread, white bread and apricot jam, cereal bar with cranberries, and cocoa drink, tested once, in different weeks along with 250ml water or 500ml fat-free milk for the cocoa drink. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
Patients attend at least 2 yoga classes per week over 5-6 weeks lasting approximately 60 minutes each for up to 15 classes during the CRT. Patients also complete surveys pre-treatment, once a week, and post-treatment over and receive a yoga manual and DVD during and after CRT.
This the first report undertaken to assess the effect of supplementation with oral gamma-aminobutyric acid (GABA), adenosine and antrosterol-containing AC mycelia on blood pressure among people with mild hypertension. Forty-one subjects with systolic blood pressure (SBP) between 130 and 179 mm Hg and/or diastolic blood pressure (DBP) between 85 and 109 mm Hg were randomized to receive either AC mycelia or starch placebo for 8 weeks, and had follow-up observation for an additional 2 weeks. SBP in the subjects given GABA, adenosine and antrosterol-rich AC mycelia significantly decreased compared to those who received the placebo (p\<0.05). DBP also decreased after the intake of AC mycelia. Compared to the placebo, AC mycelia significantly reduced plasma renin activity by a maximum of 25 % and 36 % on week 8. This suppression suggested that AC mycelia is a potent inhibitor of renin, and its bioavailability is sufficient to produce BP reduction after a short term of oral administration. Neither adverse events nor abnormal laboratory findings were noted throughout the study period, suggesting that GABA, adenosine and antrosterol-rich AC mycelia significantly decreased borderline hypertension, which may support its consideration as a safe alternative treatment compared to conventional anti-hypertensive medications.
Patients receive 177Lu-DOTATATE IV over 30 minutes every 8-16 weeks. Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity.